Remote Digital Physiologic Data Collection in Cancer: An MSK Registry Protocol

Inclusion Criteria:

Project 1: HealthKit

* Individuals who meet at least one of the following criteria:

  * Diagnosis of new onset early-stage (I-III), low-grade (I-II), or locally advanced solid tumor
  * Historical diagnosis of primary invasive solid tumor
  * Diagnosis of metastatic (stage IV) or high-grade (III-IV) disease
  * Enrolled onto an investigational trial in the EDD Service
  * Seen in the MSK UCC from 2021 and onwards
  * Completion of Survivorship Patient Self-Assessment
  * Adult without a history of cancer \<50 years of age
  * Adult without a history of cancer ≥ 50 years of age
* ≥18 years old
* Own an Apple iPhone or Android with valid operating software
* Self-reported "very well" comprehension of written and verbal English language
* Willing and able to provide informed consent and HIPAA authorization for the release of personal health information

Project 2: DigIT-Ex

Individuals who meet one of the following criteria:

* Patients at MSK who are:
* Scheduled to undergo any type of BMT (Cohort 1)
* Diagnosed with new onset AML and scheduled to initiate antineoplastic therapy (Cohort 2)
* Scheduled to undergo any surgery for prostate cancer (Cohort 3)
* Scheduled to undergo any lung cancer surgery (Cohort 4)
* Scheduled to undergo TNT for locally advanced rectal cancer (Cohort 5)
* Scheduled to initiate androgen deprivation therapy for at least 12 months and has one of the following prostate cancer diagnoses (Cohort 6):
* High risk/very high localized, locally advanced,
* Biochemically recurrent prostate cancer
* Treatment naïve, low-volume metastatic prostate cancer
* Scheduled Scheduled to undergo chemotherapy for metastatic pancreatic cancer (Cohort 7)
* Receiving outpatient care at Memorial Sloan Kettering Cancer Center (MSK)(Cohort 10)
* Diagnosed with metastatic cancer to bone For purposes of this study, metastatic bone disease includes skeletal involvement from multiple myeloma (Cohort 10)
* Scheduled for non-emergent orthopaedic surgery to stabilize lower-extremity bone metastases (Cohort 10)
* Able to undergo at least 5 consecutive days of preoperative monitoring prior to surgery (Cohort 10)
* Have had a CT scan including the L3 vertebral level within 3 months before surgery (used to assess skeletal muscle mass and sarcopenia) (Cohort 10)
* Have a ≥50% predicted likelihood of 3-month postoperative survival, as estimated by the PATHFx clinical decision-support tool (Cohort 10
* Individuals without cancer \<50 years of age (Cohort 8)
* Individuals without cancer ≥50 years of age (Cohort 9)

  * 18 to 90 years old at the time of consent
  * Willing and able to download the Withings Health Mate app onto their personal mobile device
  * Willing to provide mobile digital physiological data for a period of at least six months to a maximum of one year following consent for Cohorts 1-9, and 4 months following consent for Cohort 10.
  * Willing to provide informed consent

Exclusion Criteria:

Project 1: HealthKit

* Unable or unwilling to successfully export and /or share physiological data

Project 2: DigIT-Ex

* Unable or unwilling to appropriately use digital platforms or devices
* Require a wheelchair for ambulation (Cohort 10)
* Are undergoing stabilization surgery for a primary bone tumor (rather than metastatic disease) (Cohort 10)